此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma (SARCOGYN)

2026年11月12日 更新者:Alexander Anokhin、Blokhin's Russian Cancer Research Center

Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment

The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.

研究概览

详细说明

Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Moscow、俄罗斯
        • 招聘中
        • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
        • 接触:
        • 接触:
        • 首席研究员:
          • Alexander Anokhin, PhD
        • 副研究员:
          • Alexey Rumyantsev, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

  1. Morphologically verified uterine leiomyosarcoma
  2. Age 18 to 70 years
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  4. Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
  5. No prior systemic anticancer therapy
  6. No contraindications to doxorubicin and dacarbazine
  7. Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
  8. Measurable disease on CT or MRI prior to randomization
  9. Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
  10. Consent to the proposed chemotherapy regimen
  11. Adequate bone marrow function: absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L
  12. Adequate liver function: bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
  13. Adequate cardiac function: satisfactory left ventricular systolic function

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Doxorubicin

Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days.

Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line

其他名称:
  • 阿霉素

Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

其他名称:
  • 阿霉素
实验性的:Doxorubicin+Dacarbazine

Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days.

Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line

其他名称:
  • 阿霉素

Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

其他名称:
  • 阿霉素

Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

其他名称:
  • DTIC

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
1-year progression-free survival (PFS)
大体时间:Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)

1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS)

Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)

次要结果测量

结果测量
措施说明
大体时间
Overall Survival
大体时间:Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)

OS is defined as time from enrollment to death due to any cause

Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
Objective Response Rate
大体时间:After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days

Proportion of patients achieving complete or partial response per RECIST 1.1

After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
incidence of Adverse events
大体时间:During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks

Proportion of patients experiencing adverse events in each treatment arm

During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年1月24日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年1月1日

研究注册日期

首次提交

2026年10月23日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅